All In Biotech

Drug Trial Radar · NCT01837745

Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?

Last checked: Nov 19, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 776 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

776

Actual

Start

May 13, 2013

Primary completion

Apr 1, 2022

Study completion Jan 1, 2030

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label randomized phase III trial, using a non-inferiority comparison design. After randomization,patients will receive either post-operative radioiodine ablation with an activity of 1.1 GBq (30 mCi) after stimulation by rhTSH, and then be followed-up (ablation group) or be followed-up (without postoperative radioiodine ablation) (follow-up group). The objective is to assess the non-inferiority of the proportion of patients without tumor-related event evaluated at three years after randomisation in the absence of radioiodine ablation (follow-up group) compared to the ablation group, in patients with low-risk differentiated thyroid cancer treated with total thyroidectomy with or without lymph node dissection (pT1am N0 or Nx, pT1b N0 or Nx)

Conditions

  • Low Risk Differentiated Thyroid Cancer

Interventions

  • rhTSH stimulationDrug

    Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment

  • I131Drug

    An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.

  • Follow upOther

    * 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation * 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4) * 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 4 years (+/- 2 months) after randomization: a serum Tg/LT4 * 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4 * 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of patient without event at 3 years following randomizationTime frame: assessed up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, Val De Marne, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.